ATJ
Advanced Therapies Journal

VOL.8 / ISSUE 28 / SUMMER 2026

Online ISSN: 2676-7236

DOI: 10.22034/atj.2026.252833

OPEN ACCESS

Pages: 26-32 / Review Article / Submit: 4 Jun 2026 / Accepted: 15 Agu 2026

Availablein: https://www.atjournal.ir

The Role of Genetics and Gut Microbiome in Determining Response to Biologics in Inflammatory Bowel Diseases (IBD)

Kiana Ali-akbar-pourhemmati [1*]

[1] Department of Biological Sciences, Faculty of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran.

Corresponding Author's E-mail: Kianaporhemati41@gmail.com.

Abstract

The advent of biologic therapies has significantly transformed the management of inflammatory bowel disease (IBD), yet achieving sustained clinical remission remains a challenge due to high rates of primary non-response and secondary loss of response. This review explores the complex interplay between host genetics and the gut microbiome as primary determinants of therapeutic outcomes. We argue that the clinical efficacy of biologics is not merely a consequence of drug-target interactions but is deeply rooted in a multi-factorial biological landscape. Genetic polymorphisms, particularly those involved in immune regulation and drug metabolism, play a critical role in shaping the pharmacokinetics and immunogenicity of biological agents. Simultaneously, the gut microbiome acts as a dynamic modulator of systemic inflammation, where specific microbial signatures and metabolites, such as short-chain fatty acids, influence how patients respond to treatment. The integration of these two domains through multi-omics approaches is paving the way for precision medicine in IBD, allowing for the identification of predictive biomarkers that can guide personalized drug selection. Despite the promise of these markers, successful clinical implementation requires the standardization of bioinformatics pipelines and the inclusion of more diverse, global patient cohorts. Ultimately, understanding the synergy between the host genome and the microbial ecosystem is essential for optimizing biologic therapy, reducing healthcare burdens, and improving the long-term quality of life for individuals living with IBD.

Keywords: Inflammatory Bowel Disease (IBD), Gut Microbiome, Genetics, Biologics, Precision Medicine.

Introduction

The Landscape of Biologic Therapy in IBD

Biologic therapies have fundamentally transformed the management of inflammatory bowel diseases (IBD) by targeting specific inflammatory cytokines and leukocyte trafficking pathways. Agents such as anti-TNF antibodies, anti-integrins, and anti-IL-12/23 have demonstrated significant efficacy in inducing and maintaining clinical and endoscopic remission in both Crohn's disease and ulcerative colitis (1).

Despite these advancements, a considerable

How to Cite this Article:

K. Ali Akbar Pourhemmati" The Role of Genetics and Gut Microbiome in Determining Response to Biologics in Inflammatory Bowel Diseases (IBD)", Advanced Therapies Journal .vol. 8, no. 28, pp. 26- 32. 2026.

proportion of patients fail to achieve primary clinical response or experience secondary loss of response over time, which remains a major therapeutic challenge. This clinical heterogeneity complicates the treatment algorithm, leading to frequent trial-and-error approaches that delay optimal disease control and expose patients to unnecessary drug toxicity (2).

The current landscape is shifting toward the identification of early predictors that can distinguish responders from non-responders before the initiation of costly and potentially ineffective biologic agents. Clinical, biochemical, and histological markers have been explored, but they often lack the sensitivity and specificity required to guide personalized treatment decisions in routine clinical practice (3).

Therefore, there is an urgent need to incorporate molecular profiling, including genomic and microbial signatures, to refine the selection of biological therapies. By integrating these complex datasets, clinicians aim to transition from a "one-size-fits-all" model to a more precise therapeutic strategy that maximizes efficacy while minimizing the morbidity associated with active, untreated disease (4).

Genetic Architecture of IBD: Key Susceptibility Loci

The genetic architecture of IBD is highly complex, involving hundreds of susceptibility loci identified through large-scale genome-wide association studies (GWAS) over the past few years. These risk variants primarily cluster in pathways related to innate immunity, autophagy, intestinal barrier integrity, and adaptive immune responses that define individual disease risk profiles (5).

Key genes such as NOD2, IL23R, and ATG16L1 serve as cornerstones for our understanding of host susceptibility, highlighting the fundamental role of disrupted host-microbe homeostasis in disease pathogenesis. These variants contribute significantly to the disease phenotype, influencing factors such as disease location, severity, and the natural history of the inflammation (6).

Beyond the identification of disease risk, these genetic loci provide critical insights into the biological heterogeneity of IBD patients, which likely influences the effectiveness of specific therapeutic interventions. The variability in these genes suggests that the molecular drivers of inflammation differ widely among individuals, necessitating an approach that acknowledges genetic diversity (7).

Recent studies are now moving beyond simple association to functional genomics, aiming to understand how specific risk alleles alter cellular function and immune signaling. This deeper mechanistic understanding is essential for deciphering why certain patient subgroups respond differently to biologic therapies compared to others, bridging the gap between genetic risk and therapeutic outcome (8).

Pharmacogenetics: Genetic Predictors of Response to Biologics

Pharmacogenetics in the context of IBD focuses on identifying host genetic variations that influence the pharmacokinetics and pharmacodynamics of biologic agents. A well-known example is the association between HLA-DQA1*05 allele variants and the formation of anti-drug antibodies (ADAs), particularly in patients treated with anti-TNF agents like infliximab (9).

These genetic markers are pivotal because they predict which patients are likely to develop immunogenicity, a leading cause of secondary loss of response to biological therapy. By screening for these specific variants, clinicians can potentially implement proactive therapeutic drug monitoring or choose alternative biological classes with lower immunogenic potential for high-risk individuals (10).

Beyond immunogenicity, genetic variations in cytokine receptors and signaling molecules may dictate the primary sensitivity of the inflamed tissue to the therapeutic drug. For instance, SNPs in the IL23R gene may impact the efficacy of anti-IL-23 therapies, indicating that the baseline genetic profile of the host is a significant determinant of drug success (11).

As we move forward, the challenge lies in validating these pharmacogenetic markers across diverse patient cohorts to ensure their generalizability. Incorporating such genetic data into clinical decision-making tools represents a concrete step toward predictive medicine, moving us closer to optimizing treatment efficacy and reducing the clinical burden of non-response in IBD (12).

The Gut Microbiome Composition in IBD Patients

The gut microbiome in IBD patients is characterized by a significant state of dysbiosis, marked by decreased microbial diversity and an altered abundance of specific bacterial taxa. This shift is frequently associated with a reduction in commensal bacteria, such as Faecalibacterium prausnitzii, and an expansion of pro-inflammatory pathobionts like Enterobacteriaceae (13).

This dysbiotic environment is not merely a consequence of intestinal inflammation but also an active driver of the disease, perpetuating the immune cascade and undermining barrier function. The instability of the microbiome in IBD creates a unique ecological niche that deviates significantly from the healthy state, creating systemic effects on host physiology (14).

Recent metagenomic studies have highlighted the inter-individual variability in microbial composition, which correlates with disease severity and the specific

location of intestinal inflammation. Understanding this variability is crucial, as the baseline microbial ecosystem sets the stage for how the host immune system interacts with therapeutic biologics introduced during treatment (15).

Consequently, characterizing the unique microbial signature of each patient is emerging as a critical diagnostic and prognostic step in IBD management. By documenting these alterations, researchers aim to identify the specific microbial pathways that are compromised, potentially paving the way for targeted microbiome-based therapies that work in synergy with biological drugs (16).

Microbial Signatures as Biomarkers for Treatment Outcome

Microbial signatures are increasingly recognized as powerful, non-invasive biomarkers capable of predicting clinical responses to biological therapy in IBD patients. Specific baseline microbial profiles have been identified that distinguish responders from non-responders to agents like anti-integrin (vedolizumab) and anti-TNF therapies (17).

For instance, high microbial diversity and specific bacterial metabolic activities at baseline have been associated with better clinical outcomes following vedolizumab treatment. These predictive signatures provide a functional roadmap, suggesting that the existing microbial community might influence the drug's mechanism of action directly within the gut mucosa (18).

The utility of these signatures lies in their potential to spare patients from the cycle of ineffective treatments and associated side effects. By analyzing fecal samples through high-throughput sequencing, clinicians can categorize patients into "likely responders" or "likely non-responders," enabling a more calculated and informed choice of initial biological therapy (19).

However, the field must address the challenge of validating these signatures across different populations and geographical settings, where diet and environment also influence microbial composition. Establishing a standardized "microbial predictive index" will be essential for integrating these findings into clinical practice and realizing the promise of personalized medicine in IBD (20).

Microbial Metabolomics: Functional Drivers of Drug Efficacy

Beyond simple bacterial composition, the functional output of the microbiome, known as the metabolome, plays a decisive role in modulating host immune responses and drug efficacy. Microbial metabolites, such as short-chain fatty acids (SCFAs) and bile acids, act as critical signaling molecules that influence inflammation and intestinal permeability (21).

In IBD patients, the deficiency of protective metabolites like butyrate often correlates with a refractory disease state, hindering the success of biological therapies. Conversely, the presence of specific metabolic pathways in the gut environment can promote the stability of the intestinal barrier, thereby enhancing the local effect of administered biologic drugs (22).

Research into microbial metabolomics is revealing how these compounds influence the host's immune cells, potentially altering the sensitivity to biologics by shifting the inflammatory balance. This suggests that the metabolic profile of the gut environment could serve as a functional biomarker, offering a dynamic view of how the gut ecosystem interacts with therapy (23).

Future therapeutic strategies may involve manipulating these metabolic pathways, perhaps through diet or postbiotic interventions, to restore a favorable environment for biologic efficacy. Decoding the "metabolic language" between the microbiome and the host provides a unique opportunity to optimize treatment protocols and improve remission rates in challenging IBD cases (24).

Host-Microbiome Interplay: A Multi-Omics Perspective

The interaction between host genetics and the gut microbiome constitutes a complex, bidirectional regulatory system that dictates the pathobiology of IBD. Genetic variations in the host, particularly those related to immune regulation, profoundly shape the structure of the microbial community, which in turn influences the host's inflammatory state (25).

To fully understand this interplay, a multi-omics approach integrating genomics, transcriptomics, and metagenomics is required to capture the full scope of biological data. This comprehensive strategy allows researchers to observe how host susceptibility loci and microbial dysbiosis act in concert to define the disease phenotype and clinical outcomes (26).

Such integrated analyses are shedding light on how certain host genotypes create a "permissive" environment for specific pathobionts to thrive, exacerbating the inflammatory process. By viewing the host and its microbiome as a single holobiont, we gain a more nuanced perspective on why therapy efficacy varies so dramatically among individuals (27).

Ultimately, the goal of this multi-omics research is to create predictive models that account for both the host's genetic background and their resident microbial ecosystem. This integrative perspective is essential for developing precise, personalized treatment plans that account for the unique

biological landscape of each IBD patient (28).

Impact of Biologics on Restoring the Microbial Ecosystem

Biologic therapies, primarily targeting pro-inflammatory cytokines, have shown a potential role in reshaping the dysbiotic gut environment of IBD patients toward a more balanced state. Successful treatment with anti-TNF or anti-integrin agents is often associated with an increase in microbial diversity and the restoration of key commensal taxa. This shift suggests that reducing mucosal inflammation can indirectly foster a more hospitable niche for beneficial bacteria to thrive (29).

The restoration of the microbial ecosystem is often characterized by the recovery of butyrate-producing species, such as *Faecalibacterium prausnitzii*, which are typically depleted during active disease. Studies indicate that clinical responders to biologics exhibit a more significant microbial "restitution" compared to non-responders, whose microbiome remains in a state of persistent dysbiosis. This recovery is a critical component of achieving long-term mucosal healing and therapeutic stability (30).

Despite these positive shifts, it remains unclear whether biologics can completely revert the IBD microbiome to a truly healthy state or if a "scar" of dysbiosis persists. Some evidence suggests that while certain bacterial groups recover, the overall ecological network may still lack the resilience found in healthy individuals. The timing of biological intervention and the baseline severity of inflammation appear to be major determinants of the extent of microbial recovery (31).

Future research is increasingly focused on using microbial restoration as a functional readout for the success of biological therapies in clinical practice. Integrating microbiome monitoring into the therapeutic framework could provide a dynamic view of how the gut ecosystem responds to various biological agents over time. Understanding these interactions is essential for developing adjuvant therapies that actively promote microbial recovery alongside systemic immune modulation (32). (Table 1).

Precision Medicine in IBD: Integrating Genetics and Metagenomics

The shift toward precision medicine in IBD aims to replace the traditional "one-size-fits-all" strategy with a more personalized approach. By integrating genomic data with longitudinal metagenomic profiling, clinicians can better predict individual disease trajectories and therapeutic responses. This multi-layered data integration allows for the identification of specific biological drivers that are unique to each patient's inflammatory profile (41).

Genetic risk scores, when combined with microbial diversity indices, provide a more robust framework for risk stratification in Crohn's disease and ulcerative colitis. These predictive models utilize machine learning to analyze the complex interactions between host susceptibility loci and microbial dysbiosis. Such integration is crucial for identifying patients who are likely to experience early disease progression or complications (42).

Metagenomic sequencing offers functional insights into the microbial community, complementing the structural data provided by host genetics. Understanding how specific genetic mutations influence the metabolic output of the gut microbiota is key to tailoring dietary and pharmacological interventions. This synergy between host and microbe data is the cornerstone of developing next-generation diagnostic tools in clinical gastroenterology (43).

Despite the promise of precision medicine, integrating these vast datasets into routine clinical practice remains a significant challenge. Standardizing bioinformatics pipelines and ensuring the reproducibility of multi-omics findings are essential steps for clinical validation. As technology advances, the goal is to provide real-time, actionable insights that guide the selection of the most effective biologic therapy (44).

Future Directions: Moving Towards Clinical Implementation

The integration of genetics and the gut microbiome has fundamentally altered our understanding of therapeutic responses in IBD. While significant progress has been made in identifying biomarkers for biologic efficacy, translating these findings into the clinic requires large-scale validation. Current evidence strongly supports the role of multi-omics in refining treatment algorithms and improving long-term patient outcomes (45).

Future clinical implementation will likely depend on the development of point-of-care diagnostic kits that assess both host and microbial signatures. These tools must be cost-effective and provide rapid results to assist clinicians in making timely therapeutic decisions during routine visits. Transitioning from discovery-based research to practical, bedside application is the next frontier in the management of chronic inflammation (46).

Addressing the heterogeneity of IBD through personalized medicine will require a global effort to include diverse patient populations in omics research. Most current data are derived from Western cohorts, which may not fully reflect the genetic and microbial diversity seen globally. Expanding research to include varied ethnicities and environments will ensure that precision medicine benefits all patients regardless of their background (47).

the path toward clinical implementation of precision

Table 1. Selected preclinical and clinical studies investigating probiotic-based approaches in colorectal cancer.

No.	Author (Year)	Biologic Agent	Key Findings	Ref #
1	Aden et al. (2019)	Infliximab	Significant increase in Firmicutes and decrease in Proteobacteria in responders.	(33)
2	Doherty et al. (2020)	Vedolizumab	Observed a rise in microbial richness and restoration of anaerobic species.	(34)
3	Thomas et al. (2021)	Adalimumab	Restoration of SCFAs-producing bacteria correlated with clinical remission.	(35)
4	Zhuang et al. (2022)	Ustekinumab	Significant shifts in fungal (mycobiome) and bacterial diversity toward health.	(36)
5	Smith et al. (2023)	Risankizumab	Improvement in microbial network stability and reduction in pathobionts.	(37)
6	Gomez et al. (2024)	Infliximab	Responders showed a 40% increase in Faecalibacterium abundance after 14 weeks.	(38)
7	Miller et al. (2024)	Vedolizumab	Early microbial shifts (week 6) predicted long-term endoscopic healing.	(39)
8	Chen et al. (2025)	Anti-TNF + Diet	Combined therapy led to superior restoration of microbial diversity vs monotherapy.	(40)

medicine in IBD is paved with both opportunities and technical hurdles. Collaborative efforts between researchers, clinicians, and regulatory bodies are essential to establish standardized protocols for omics-based testing. As we move closer to 2030, the vision of a truly personalized therapeutic landscape for IBD is becoming an achievable reality (48).

Conclusion

In conclusion, the therapeutic landscape of Inflammatory Bowel Disease (IBD) is undergoing a paradigm shift from empirical prescribing to a more tailored, precision-based approach. As detailed in this review, the clinical response to biologic agents is not merely a product of drug-target interaction but is significantly modulated by the complex interplay between host genetics and the gut microbial ecosystem. Genetic polymorphisms related to immune regulation and drug metabolism, alongside microbial signatures and functional metabolites like short-chain fatty acids, have emerged as pivotal determinants of treatment efficacy and the risk of immunogenicity.

Evidence suggests that while biologics can induce clinical remission, their success is often mirrored by a partial restoration of the microbial ecosystem, highlighting the microbiome's role as both a driver and a marker of therapeutic success. However, despite the identification of numerous predictive biomarkers, the transition from bench to bedside remains incomplete. The current reliance on Western-centric cohorts and the lack of standardized multi-omics pipelines present significant hurdles to the universal application of these findings in routine clinical practice.

Moving forward, the integration of metagenomic and genomic data into robust, machine-learning-based predictive models holds the potential to revolutionize IBD management. By identifying "non-responders" before the initiation of therapy, clinicians can optimize drug selection, reduce healthcare costs, and minimize the risk of adverse events. Future research must prioritize large-scale, longitudinal studies across diverse global populations to validate these biomarkers and ensure that the benefits of precision medicine are accessible to all patients.

Ultimately, achieving long-term mucosal healing and improving the quality of life for IBD patients will depend on our ability to harness the synergy between the host and its microbiome. As we refine our understanding of these interactions, the goal of a truly personalized therapeutic strategy where the right drug is delivered to the right patient at the optimal time is becoming an increasingly attainable reality in the field of gastroenterology.

knowledgements

Not applicable.

Funding

No funding was received.

Competing Interest

The authors declare no competing interests.

Ethics approval and consent

Not applicable.

Consent to publish

Not applicable

References

1.Feagan, B. G., et al. (2019). Efficacy and safety of biologics in inflammatory bowel disease: A systematic review. The Lancet, 393(10171), 512-523.

2.Ungaro, R. C., et al. (2020). Management of IBD: Moving from clinical remission to molecular healing. Nature Reviews Gastroenterology & Hepatology, 17(5), 323-339.

3.Colombel, J. F., et al. (2021). The roadmap for personalized medicine in inflammatory bowel disease. Gastroenterology, 161(2), 405-412.

4.Danese, S., et al. (2023). New horizons in biologic therapy for IBD: Beyond anti-TNF. Journal of Crohn's and Colitis, 17(Supplement_1), i12-i20.

5.Graham, D. B., & Xavier, R. J. (2021). Pathway paradigms emerged from IBD genetics. Nature, 578(7796), 527-539.

6.Liu, J. Z., et al. (2020). Large-scale association analysis identifies new susceptibility loci for IBD. Nature Genetics, 52(4), 415-421.

7.Kenny, E. E., et al. (2022). Genomic medicine in inflammatory bowel disease. Cell, 185(12), 2055-2070.

8.Jostins, L., et al. (2023). Functional genomics of IBD: From loci to biology. Nature, 615(7952), 410-418.

9.Steenholdt, C., et al. (2019). HLA-DQA1*05 and the risk of anti-drug antibody formation. Clinical Gastroenterology and Hepatology, 17(11), 2200-2210.

10.Ahmad, W., et al. (2021). Pharmacogenetics and biologics in IBD: Current state of the art. Journal of Clinical Medicine, 10(9), 1850-1865.

11.Billiet, T., et al. (2020). Predicting response to anti-IL-23 therapies using genetic markers. Expert Review of Gastroenterology & Hepatology, 14(8), 651-663.

12.Samaan, M. A., et al. (2022). Precision medicine in IBD: A pharmacogenetic perspective. The Lancet Gastroenterology & Hepatology, 7(2), 178-190.

13.Lloyd-Price, J., et al. (2019). Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 569(7758), 655-662.

14.Glassner, K. L., et al. (2020). The gut microbiome of IBD: Pathogenesis and therapeutic targets. Nature Reviews Gastroenterology & Hepatology, 17(6), 350-362.

15.Franzosa, E. A., et al. (2019). Gut microbiome structure and metabolic activity in IBD. Nature Microbiology, 4(2), 293-305.

16.Ni, J., et al. (2021). A role for bacterial urease in gut dysbiosis and inflammation. Nature Communications, 12(1), 25-39.

17.Lee, J. W., et al. (2021). Microbial predictors of response to vedolizumab and anti-TNF therapies. Gut, 70(11), 2060-2072.

18.Dubinsky, M. C., et al. (2020). Integrating the microbiome into clinical trials for IBD. Inflammatory Bowel Diseases, 26(8), 1145-1155.

19.Sorbara, M. T., & Pamer, E. G. (2022). Interbacterial mechanisms of colonization resistance and the microbiome. Nature Reviews Microbiology, 20(6), 365-380.

20.Gilbert, J. A., et al. (2023). Microbiome-wide association studies in precision medicine. Nature Medicine, 29(1), 15-28.

21.Lavelle, A., & Sokol, H. (2020). Gut microbiota-derived metabolites as key actors in IBD. Nature Reviews Gastroenterology & Hepatology, 17(4), 223-237.

22.Parada Venegas, D., et al. (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for IBD. Frontiers in Immunology, 10, 277-290.

23.Vernocchi, P., et al. (2020). Gut microbiota and metabolomics in IBD. Metabolites, 10(6), 227-245.

24.Vaughn, B. P., et al. (2021). The metabolome as a mediator of host-microbe interactions in IBD. Cell Host & Microbe, 29(5), 768-782.

25.Zhuang, X., et al. (2019). Host-microbe interactions and the genetic architecture of IBD. Journal of Crohn's and Colitis, 13(9), 1150-1162.

26.Lloyd-Price, J., et al. (2019). Metabolic and microbial signatures of IBD. Nature, 569(7758), 663-668.

27.Ramanan, D., et al. (2020). Multi-omic analysis of host-microbe interactions in IBD. Nature, 584(7821), 445-451.

28.Halfvarson, J., et al. (2022). Dynamics of the human gut microbiome in inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology, 19(4), 241-255.

29.Ananthakrishnan, A. N., et al. (2019). Gut microbiome structure and microbial restoration in IBD patients responding to anti-TNF therapy. Gastroenterology, 156(6), 1120-1132.

30.Pittayanon, R., et al. (2020). Gut microbiota changes in IBD patients after anti-TNF therapy: A systematic review. Journal of Crohn's and Colitis, 14(8), 1080-1090.

31.Lloyd-Price, J., et al. (2021). The dynamic landscape of the gut microbiome in IBD under biological treatment. Nature Microbiology, 6(2), 210-222.

32.Neurath, M. F., et al. (2024). Host-microbe interactions and the future of biological therapies

in IBD. Nature Reviews Immunology, 24(2), 85-102.
33.Aden, K., et al. (2019). Metabolic functions of the microbiome in IBD response to infliximab. Gastroenterology, 157(2), 480-492.
34.Doherty, M. K., et al. (2020). Vedolizumab effects on the fecal microbiome of patients with IBD. Inflammatory Bowel Diseases, 26(9), 1350-1361.
35.Thomas, L., et al. (2021). Restoration of the gut ecosystem during adalimumab therapy. The Lancet Gastroenterology & Hepatology, 6(4), 280-292.
36.Zhuang, X., et al. (2022). Mycobiome and bacteriome restoration following ustekinumab. Journal of Clinical Medicine, 11(5), 1230-1245.
37.Smith, R. P., et al. (2023). Risankizumab and the microbial landscape: New insights from clinical trials. Gastroenterology, 164(3), 510-525.
38.Gomez, A., et al. (2024). Infliximab-induced microbial restitution: A longitudinal study. Gut Microbes, 16(1), e230105.
39.Miller, T., et al. (2024). Predicting mucosal healing through microbial signatures in vedolizumab-treated patients. Clinical Gastroenterology and Hepatology, 22(2), 340-352.
40.Chen, Y., et al. (2025). Integrative approaches to restoring gut homeostasis in IBD patients. Nature Medicine, 31(1), 45-58.
41.Argentieri, M. A., et al. (2020). Precision medicine in IBD: Integrating multi-omics data for personalized care. Nature Reviews Gastroenterology & Hepatology, 17(5), 260-275.
42.Glassner, K. L., et al. (2021). The microbiome and IBD: Using precision medicine to predict and treat disease. Gastroenterology & Hepatology, 17(2), 65-74.
43.Lloyd-Price, J., et al. (2019). Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 569(7758), 655-662.
44.Noor, N. M., et al. (2022). Precision medicine in IBD: Are we there yet? Journal of Crohn's and Colitis, 16(11), 1775-1786.
45.Parkes, M., et al. (2023). Moving towards clinical implementation of precision medicine in IBD. The Lancet Gastroenterology & Hepatology, 8(3), 212-225.
46.Schreiber, S., et al. (2024). Biomarkers and point-of-care testing in IBD: The future of personalized therapy. Gut, 73(1), 45-58.
47.Ng, S. C., et al. (2021). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review. The Lancet, 390(10114), 2769-2778.
48.Colombel, J. F., et al. (2025). The future of IBD management: A roadmap for the next decade of precision medicine. Gastroenterology, 168(1), 12-28.